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ABSTRACT
Background Low back pain is one of the leading 
causes of disability worldwide. Exercise therapy is widely 
recommended to treat persistent non- specific low back 
pain. While evidence suggests exercise is, on average, 
moderately effective, there remains uncertainty about 
which individuals might benefit the most from exercise.
Methods In parallel with a Cochrane review update, 
we requested individual participant data (IPD) from 
high- quality randomised clinical trials of adults with our 
two primary outcomes of interest, pain and functional 
limitations, and calculated global recovery. We compiled 
a master data set including baseline participant 
characteristics, exercise and comparison characteristics, 
and outcomes at short- term, moderate- term and long- 
term follow- up. We conducted descriptive analyses and 
one- stage IPD meta- analysis using multilevel mixed- 
effects regression of the overall treatment effect and 
prespecified potential treatment effect modifiers.
Results We received IPD for 27 trials (3514 
participants). For studies included in this analysis, 
compared with no treatment/usual care, exercise therapy 
on average reduced pain (mean effect/100 (95% CI) 
−10.7 (−14.1 to –7.4)), a result compatible with a 
clinically important 20% smallest worthwhile effect. 
Exercise therapy reduced functional limitations with a 
clinically important 23% improvement (mean effect/100 
(95% CI) −10.2 (−13.2 to –7.3)) at short- term 
follow- up. Not having heavy physical demands at work 
and medication use for low back pain were potential 
treatment effect modifiers—these were associated 
with superior exercise outcomes relative to non- 
exercise comparisons. Lower body mass index was also 
associated with better outcomes in exercise compared 
with no treatment/usual care. This study was limited by 
inconsistent availability and measurement of participant 
characteristics.
Conclusions This study provides potentially useful 
information to help treat patients and design future 
studies of exercise interventions that are better matched 
to specific subgroups.
Protocol publication https:// doi. org/ 10. 1186/ 2046- 
4053- 1- 64
InTRoduCTIon
Low back pain is one of the leading causes of 
disability worldwide and has a substantial socioeco-
nomic impact.1–4 The majority of the cost associated 
with low back pain is generated by individuals with 
persistent symptoms.2 5 Both the prevalence and 
the cost of persistent low back pain are increasing.2 
Exercise therapy is widely recommended to treat 
persistent low back pain and is one of several inter-
ventions that are moderately effective in reducing 
pain and improving function.6
Identifying subgroups of individuals who may 
benefit more from treatment, and potential treat-
ment effect modifiers (also known as moderators or 
treatment–covariate interactions), is an important 
goal in health research. There are difficulties with 
most existing subgroup/classification systems for 
patients with low back pain; these include unclear 
reliability or validity in clinical practice, lack of 
comprehensive predictor variables, and inclusion 
of measures or information that is not useful, nor 
feasibly collected in practice.7 Furthermore, most 
low back pain trials are not designed to detect treat-
ment effect modifiers.8 9
Our team conducted a Cochrane review where 
we concluded that exercise therapy appears to be 
effective in decreasing pain and improving function 
in adults with persistent low back pain; however, 
this work was limited by inclusion of only published 
‘aggregate’ data, such as overall treatment effects 
and average patient characteristics.10–12 Individual 
participant data (IPD) meta- analysis standardises 
analyses across trials, allowing for more powerful 
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and reliable examination of differential treatment effects across 
subgroups of individuals,13 14 since within- trial information can 
be used to estimate how individual characteristics modify treat-
ment benefit.15
Our primary objective in this study was to assess the treat-
ment effect of exercise therapy for reducing pain and functional 
limitations in adults with persistent low back pain, as well as any 
modification of treatment effect by considering a set of plau-
sible patient features. We aimed to identify the characteristics of 
persons with low back pain who are more likely to benefit from 
exercise therapy.
MATeRIAlS And MeThodS
We used standard systematic review methods advocated by 
Cochrane Back and Neck to identify eligible trials.16 For this IPD 
meta- analysis, we identified randomised controlled trials from 
an updated search conducted in 2013 for the Cochrane review, 
‘Exercise therapy for treatment of chronic low back pain’. 
Complete descriptions of the full search strategy, screening, 
selection and trial- level data extraction for the related Cochrane 
review are reported elsewhere.10 The protocol for this IPD study 
has been published.17
Eligible trials evaluated all forms of exercise therapy compared 
with any or no other interventions in adults (>18 years of age) 
with non- specific persistent (>12 weeks’ duration) low back 
pain (alone or with leg pain). Trials with mixed subacute (>6 
weeks’ duration) and persistent low back pain populations were 
eligible for the IPD meta- analysis if it was possible to extract 
information exclusively for those participants experiencing 
persistent low back pain.
For retrieval of IPD, we selected trials included in the updated 
Cochrane review that were rated as moderate to low risk of bias. 
Following Cochrane Back and Neck Methods Guidelines, we 
defined moderate to low risk of bias as at least 6 of 12 recom-
mended items rated as having low risk of bias18; these risk of bias 
items align with the current Cochrane Back and Neck Methods 
Guidelines.16
data collection and management
The original IPD was requested from the authors of 56 eligible 
trials. We extracted trial- level information about each eligible 
trial (details can be found in our Cochrane review protocol10) 
and included IPD reported characteristics of the trial sample, 
variables collected at baseline and at follow- up periods, and 
subgroup and treatment effect modifiers investigated and 
presented in the trial report.
For eligible trials that provided their IPD, each raw data 
set was saved on a secure server at Dalhousie University in its 
original format before being converted to a common format. 
We evaluated the IPD received from each trial and compared 
it with the available related publication(s) based on descriptive 
summary, range of included variables and missing observations. 
We attempted to use the IPD from each trial to replicate results 
reported in the original publications, including baseline charac-
teristic descriptive analyses and advanced analyses of outcome 
data at each available follow- up period, by reproducing the 
statistical analyses as reported by the trial authors. We discussed 
and clarified any discrepancies or missing information between 
our results and those presented in each original publication with 
the original trial authors. Ultimately, we included only trial data 
where we could reproduce published trial findings or explain/
clarify discrepancies. Once data checks were complete and satis-
factory, individual trial data sets were combined to form a new 
master data set with a variable added to indicate the original 
trial.
data preparation
We used a prespecified framework for mapping, classifying 
and renaming sufficiently similar variables (defined following 
the variable map presented in Hayden et al5). Potential treat-
ment effect modifiers included variables in the following broad 
domains: participant sociodemographic characteristics, lifestyle 
factors, overall health, psychological status, previous low back 
pain, characteristics of the current episode and physical exam-
ination findings. For all variables, we preferentially selected 
the most valid and reliable measures available in each data set, 
based on supporting literature. Whenever possible, we main-
tained variables measured continuously in their continuous 
data form, while also creating categorical or dichotomous vari-
ables, as necessary, for homogeneity across studies. We assessed 
participant- level missing data on variables and outcomes. Indi-
vidual subjects with missing data within each trial were excluded 
from specific analyses, as necessary.
data analysis
Descriptive analyses
We described trial- level and participant- level characteristics of 
the included trials. We compared trial- level characteristics from 
trials included in the IPD analysis with those from eligible trials 
from the Cochrane review update to determine whether the IPD 
trials available were a representative sample of the full set of 
eligible trials.19
Meta- analyses of the overall effect of any type of exercise 
therapy compared with no treatment, non- exercise usual care 
and other conservative treatments were conducted as part of the 
associated Cochrane review based on aggregate data presented 
in the publications of primary studies (in preparation10). In this 
study, we compared published aggregate treatment effect results 
of exercise therapy versus any non- exercise comparisons from 
trials available for the IPD analysis with those from eligible 
studies in the Cochrane review update that did not provide IPD.
Our primary outcomes of interest were pain intensity, back- 
related functional limitations and a composite measure of global 
recovery. Pain and back- related functional limitations outcomes 
were self- reported as continuous measures and mainly analysed 
on the continuous scale to avoid losing power. To achieve this, 
as outcome scales varied across studies, we converted each trial’s 
outcome data to a common 0–100 scale to facilitate synthesis 
across studies and interpretability of the IPD meta- analysis 
results. We also calculated global recovery as a dichotomous 
measure of clinically important individual pain or functional 
limitations response as any improvement in score ≥30% of its 
baseline value with a minimum value of 20- point (/100) improve-
ment in pain20 or 10- point (/100) improvement in function.21–23 
We collected existing outcome data for all available time periods. 
We assessed outcomes at short- term follow- up (post- treatment 
time period closest to 3 months) for primary analyses, and for 
moderate- term (time period closest to 6 months) and long- 
term (time period closest to 12 months) follow- up in sensitivity 
analyses.
IPD syntheses
For synthesis of IPD, we employed a one- stage meta- analysis 
approach, as specified in our protocol, using multilevel mixed- 
effects linear regression for continuous pain and functional limita-
tions outcomes using restricted maximum likelihood estimation, 
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and multilevel mixed- effects logistic regression for dichotomous 
global recovery outcome using maximum likelihood estimation, 
accounting for the clustering of individuals within studies.24 25 
These models specified a random treatment effect (to allow for 
between- trial heterogeneity in effect), trial- specific intercepts (to 
account for clustering) and random effects for baseline values of 
outcome variables (to allow for between- trial heterogeneity). We 
assessed the effectiveness of exercise therapy compared with no 
treatment or usual care, and compared with other conservative 
treatments, including adjustment for the baseline value of the 
outcome of interest (ie, pain or functional limitations, as appro-
priate; functional limitations for global recovery outcome).
We extended the one- stage IPD meta- analysis framework 
to assess potential treatment effect modifiers (ie, differences 
between subgroups) related to effectiveness of exercise therapy 
compared with any other studied non- exercise treatments. We 
identified candidate treatment effect modifiers from available 
data by considering potential mechanisms for modification 
of treatment response (biological reasoning and by under-
standing the mechanism by which response is modified), and 
from existing prognostic research (treatment effect modifica-
tion studies26 and prognostic factor studies27). These were age, 
sex, level of education, current smoker, physical activity, body 
mass index (BMI), history of low back pain, work status, sick 
leave for the past 12 months, heavy physical demands at work, 
general health, general mental health, fear avoidance beliefs, 
social support, low back pain duration, baseline pain and func-
tional limitations, leg pain symptoms, and medication use for 
low back pain.
To identify potential treatment effect modifiers, we examined 
interaction terms between treatment and each variable to assess 
subgroup effects using unadjusted and adjusted models. Inter-
action coefficients for dichotomous variables are interpreted as 
the effect of exercise treatment, relative to non- exercise compar-
isons, in those with the baseline characteristic compared with 
those who do not have the characteristic. Interaction coefficients 
for continuous variables are interpreted as the additional benefit 
of exercise therapy, relative to non- exercise comparisons, for 
every one- unit increase in the continuous variable. Unadjusted 
models included fixed effects at the participant level and random 
effects at the trial level: baseline pain or functional limitations 
(corresponding with the outcome; functional limitations vari-
able was included for global recovery outcome), potential treat-
ment effect- modifying variable, treatment group (exercise or 
comparison), and the variable–treatment group interaction. To 
assess whether effect modifiers remained after further adjust-
ment, we also adjusted interaction analyses for age and sex (at 
the random and fixed effects levels). We centred the participant- 
level covariates about their trial- specific means to remove the 
contribution of across- trial associations of covariates and treat-
ment effects (removing the impact of potential ecological bias 
on the effect modifier estimates).28 29 Online supplementary 
appendix 1 describes the treatment effect modifier statistical 
model and sample code. For each model, participants missing 
data on any of the included variables were not included in the 
corresponding analysis.
We performed secondary analyses to explore the robustness of 
our results. We repeated the adjusted treatment effect modifier 
analyses described above to separately assess potential treatment 
effect modifiers for exercise therapy compared with no treat-
ment/usual care comparison groups or with other conserva-
tive comparison groups. We assessed potential treatment effect 
modifiers for pain, functional limitations and global recovery 
outcomes in adjusted analyses at moderate- term (time period 
closest to 6 months) and long- term (time period closest to 12 
months) follow- up.
We considered the smallest worthwhile effect for exercise 
treatment compared with no treatment/usual care on pain and 
functional limitation outcomes to be a 20% change from base-
line.30 31 We considered a variable as a potential treatment effect 
modifier using statistical and clinical importance of results. We 
report 95% CIs of summary treatment–variable interaction coef-
ficients and exact p values. For easier interpretation of results, 
we computed and present the observed treatment effect sizes 
(as mean difference (MD) for continuous outcomes and as OR 
for dichotomous outcomes, with 95% CIs) from available trial 
data for subgroups of potential treatment effect modifiers, cate-
gorising continuous variables at clinically relevant cut- points 
when possible or based on the observed median. For this forest 
plot presentation, we used uncentred values of the potential 
treatment effect modifier to calculate the mean treatment effect 
across categories. Models to determine the magnitude of poten-
tial treatment effect modifiers were adjusted using the same 
centred covariates as are described for primary analyses. For our 
primary analyses, we discuss treatment effect modifiers as poten-
tially important where a level of the participant characteristic 
changed the direction of the mean effect, with results compatible 
with a clinically important effect in one group and opposite effect 
in another group, or if a clinically important difference between 
covariate groups is greater than the proposed smallest worth-
while effect for exercise treatment (20% change from baseline 
on pain and functional limitation outcomes, and positive OR of 
2.0 or greater)30 31; we consider these results exploratory.
Descriptive analyses and one- stage IPD overall treatment 
effect meta- analyses were conducted using Stata V.15.0.32 Exten-
sion of the one- stage IPD models to include treatment effect 
modifiers was conducted in R V.3.5.2. Review Manager V.5.333 
was used for meta- analyses of published aggregate data. IPD data 
checking and replication were conducted in SPSS V.24.0 and SAS 
V.9.4.34 35
ReSulTS
Authors from 27 eligible trials, published between 2000 and 
2012,36–72 provided IPD for this study (table 1). Each trial 
included between 28 and 264 participants (median, 109), 
randomised to 1–3 exercise groups and 0–2 comparison groups 
(the most common design compared two exercise groups; 10 
trials). The mean sample size per group in the included trials was 
56 participants: four trials included more than 100 participants 
per group, and seven trials included less than 30 participants per 
group. Trials were conducted in Australia (four trials), Denmark 
(four trials), Italy (three trials), the Netherlands (three trials), 
UK (two trials), USA (two trials), Finland (two trials), one in 
each of Hong Kong, Spain, Switzerland, Sweden, Norway and 
Brazil, and one multicountry trial. Most trials were conducted 
in healthcare settings (10 trials in secondary care settings and 
6 in primary care settings); 5 trials were conducted in occupa-
tional settings and 6 in general population or mixed settings. The 
mean age by trial was between 37.0 and 60.1 years, and studies 
included 0%–78% female participants. Twenty- six of the 27 
included trials reported pain (96%) outcomes and 25 reported 
functional limitation outcomes (93%). All studies reported 
participant outcomes at short- term follow- up, with 19 and 15 
respectively reporting pain or functional limitations at moderate- 
term and long- term follow- up. Twenty- nine eligible studies 
were unable to provide their data or did not respond after four 
attempted requests for data (figure 1); the only characteristic on 
which these trials differed significantly was design of exercise 
 o
n
 June 10, 2020 at UCSF. Protected by copyright.
http://bjsm.bmj.com/
Br J Sports M
ed: first published as 10.1136/bjsports-2019-101205 on 28 November 2019. Downloaded from 
4 Hayden JA, et al. Br J Sports Med 2019;0:1–16. doi:10.1136/bjsports-2019-101205
Review
Ta
bl
e 
1 
Ch
ar
ac
te
ris
tic
s 
of
 2
7 
st
ud
ie
s 
w
ith
 d
at
a 
av
ai
la
bl
e 
fo
r I
PD
 m
et
a-
 an
al
ys
is
Tr
ia
l a
ut
ho
r, 
ye
ar
Co
un
tr
y
Po
pu
la
ti
on
 
so
ur
ce
Pa
rt
ic
ip
an
ts
%
 fe
m
al
e
M
ea
n 
ag
e
Tr
ia
l g
ro
up
s
o
ut
co
m
es
 a
va
ila
bl
e
Fo
llo
w
- u
p 
pe
ri
od
s
ex
er
ci
se
; 
co
m
pa
ri
so
n 
(n
)
Co
m
pa
ri
so
n 
ca
te
go
ry
Pa
in
 in
te
ns
it
y
Fu
nc
ti
on
al
 
lim
it
at
io
ns
Sh
or
t
M
od
er
at
e
lo
ng
Al
ba
la
de
jo
, 2
01
03
6
Sp
ai
n
Pr
im
ar
y 
ca
re
26
4
68
.2
50
.9
1;
 2
Ed
uc
at
io
n*
VA
S
RM
DQ
†
+
+
−
Ce
cc
hi
, 2
01
03
7
Ita
ly
Pr
im
ar
y 
ca
re
21
0
66
.7
58
.8
2;
 1
M
an
ua
l t
he
ra
py
Pa
in
 R
at
in
g 
Sc
al
e
RM
DQ
+
+
+
Ch
an
, 2
01
13
8
Ho
ng
 K
on
g
Pr
im
ar
y 
ca
re
46
78
.3
46
.6
2;
 0
N
/A
VA
S
Ab
er
de
en
‡
+
−
+
§
Co
st
a,
 2
00
93
9
Au
st
ra
lia
Pr
im
ar
y 
ca
re
15
4
60
.4
53
.7
1;
 1
Ø
/U
su
al
N
RS
RM
DQ
+
+
+
Du
fo
ur
, 2
01
04
0
De
nm
ar
k
Se
co
nd
ar
y 
ca
re
28
6
55
.9
40
.9
2;
 0
N
/A
VA
S
RM
DQ
+
+
+
Fe
rr
ei
ra
, 2
00
74
1
Au
st
ra
lia
Pr
im
ar
y 
ca
re
24
0
68
.8
53
.7
2;
 1
M
an
ua
l t
he
ra
py
VA
S
RM
DQ
+
+
+
G
ud
av
al
li,
 2
00
64
3
U
SA
M
ix
ed
23
5
37
.5
41
.6
1;
 1
M
an
ua
l t
he
ra
py
VA
S
RM
DQ
+
−
−
Ha
rt
vi
gs
en
, 2
01
04
4
De
nm
ar
k
Se
co
nd
ar
y 
ca
re
13
6
71
.4
46
.6
2;
 1
Ed
uc
at
io
n
LB
PR
S-
 P
LB
PR
S-
 F
+
+
+
He
lm
ho
ut
, 2
00
44
5
Th
e 
N
et
he
rla
nd
s
O
cc
up
at
io
na
l
81
0.
0
40
.9
2;
 0
N
/A
–
RM
DQ
+
+
+
Ko
ol
, 2
00
74
6
Sw
itz
er
la
nd
O
cc
up
at
io
na
l
15
1
21
.2
42
.3
2;
 0
N
/A
N
RS
–
+
−
−
Ko
um
an
ta
ki
s, 
20
05
47
U
K
Pr
im
ar
y 
ca
re
52
53
.9
37
.0
2;
 0
N
/A
VA
S
RM
DQ
+
−
−
Ku
uk
ka
ne
n,
 2
00
04
8
Fi
nl
an
d
O
cc
up
at
io
na
l
60
50
.0
40
.5
1;
 1
Ø
/U
su
al
Bo
rg
 C
R-
10
O
DI
+
+
+
Lo
ng
, 2
00
44
9
M
ul
tis
ite
¶
Se
co
nd
ar
y 
ca
re
13
3
51
.1
41
.6
3;
 0
N
/A
VA
S
RM
DQ
+
−
−
M
ac
ed
o,
 2
01
24
2
Au
st
ra
lia
M
ix
ed
17
2
59
.3
49
.2
2;
 0
N
/A
N
RS
RM
DQ
+
+
+
M
ac
ha
do
, 2
00
75
0
Br
az
il
Se
co
nd
ar
y 
ca
re
33
69
.7
43
.5
1;
 1
Ps
yc
ho
lo
gi
ca
l 
th
er
ap
y
VA
S
RM
DQ
**
+
+
−
M
eh
lin
g,
 2
00
55
1
U
SA
M
ix
ed
28
64
.3
49
.3
2;
 0
N
/A
VA
S
RM
DQ
††
+
+
−
M
or
on
e,
 2
01
15
2
Ita
ly
Se
co
nd
ar
y 
ca
re
70
64
.3
60
.1
1;
 1
Ø
/U
su
al
VA
S
O
DI
+
+
−
M
or
on
e,
 2
01
25
3
Ita
ly
Se
co
nd
ar
y 
ca
re
75
72
.0
55
.3
1;
 2
M
ul
tip
le
‡‡
VA
S
O
DI
+
+
−
Pe
te
rs
en
, 2
01
16
3
De
nm
ar
k
Se
co
nd
ar
y 
ca
re
22
4
56
.3
37
.1
2;
 0
N
/A
VA
S§
§
RM
DQ
+
−
+
Ra
sm
us
se
n-
 Ba
rr,
 
20
09
54
Sw
ed
en
M
ix
ed
71
50
.7
38
.1
2;
 0
N
/A
VA
S
O
DI
+
+
+
Ry
an
, 2
01
05
5
U
K
Se
co
nd
ar
y 
ca
re
38
65
.8
45
.3
1;
 1
Ed
uc
at
io
n
N
RS
RM
DQ
+
−
−
Sj
ög
re
n,
 2
00
65
6
Fi
nl
an
d
O
cc
up
at
io
na
l
90
73
.3
45
.7
1;
 1
Ø
/U
su
al
Bo
rg
 C
R-
10
–
+
+
−
Sm
ee
ts
, 2
00
65
7
Th
e 
N
et
he
rla
nd
s
Se
co
nd
ar
y 
ca
re
22
3
47
.1
41
.6
3;
 1
Ø
/U
su
al
VA
S
RM
DQ
+
+
+
So
re
ns
en
, 2
01
05
8
De
nm
ar
k
Se
co
nd
ar
y 
ca
re
20
7
52
.2
39
.1
1;
 1
Ed
uc
at
io
n
N
RS
RM
DQ
+
+
+
St
aa
l, 
20
04
59
Th
e 
N
et
he
rla
nd
s
O
cc
up
at
io
na
l
39
7.
7
38
.2
1;
 1
Ø
/U
su
al
N
RS
RM
DQ
+
+
+
U
ns
ga
ar
d-
 Tø
nd
el
, 
20
10
60
N
or
w
ay
M
ix
ed
10
9
69
.7
40
.1
3;
 0
N
/A
N
RS
O
DI
+
−
+
¶¶
W
aj
sw
el
ne
r, 
20
12
61
Au
st
ra
lia
G
en
er
al
87
55
.2
49
.6
2;
 0
N
/A
N
RS
PS
FS
+
+
−
*B
ot
h 
co
m
pa
ris
on
 g
ro
up
s 
ar
e 
ed
uc
at
io
n.
†S
pa
ni
sh
 R
M
DQ
.
‡C
hi
ne
se
 A
be
rd
ee
n 
Sc
al
e.
§F
un
ct
io
na
l o
ut
co
m
e 
on
ly
.
¶M
ul
tis
ite
 (C
an
ad
a,
 U
SA
, G
er
m
an
y,
 U
K,
 K
uw
ai
t).
**
Br
az
ili
an
/P
or
tu
gu
es
e 
RM
DQ
.
††
16
- it
em
 R
M
DQ
.
‡‡
G
ro
up
 1
 is
 Ø
/u
su
al
; g
ro
up
 2
 is
 b
ac
k 
sc
ho
ol
.
§§
Su
m
 o
f t
hr
ee
 V
AS
 s
ca
le
s.
¶¶
Pa
in
 o
ut
co
m
e 
on
ly
.
Ø,
 'N
o 
tr
ea
tm
en
t’ 
co
m
pa
ris
on
; B
or
g 
CR
-1
0,
 B
or
g 
Ca
te
go
ry
-  R
at
in
g 
Sc
al
e;
 F,
 fu
nc
tio
n 
sc
al
e;
 IP
D,
 in
di
vi
du
al
 p
ar
tic
ip
an
t d
at
a;
 L
BP
RS
, L
ow
 B
ac
k 
Pa
in
 R
at
in
g 
Sc
al
e;
 N
/A
, n
ot
 a
pp
lic
ab
le
; N
RS
, N
um
er
ic
 R
at
in
g 
Sc
al
e;
 O
DI
, O
sw
es
tr
y 
Di
sa
bi
lit
y 
In
de
x;
 P
, p
ai
n 
sc
al
e;
 P
SF
S,
 P
at
ie
nt
 
Sp
ec
ifi
c 
Fu
nc
tio
na
l S
ca
le
; Q
BP
DS
, Q
ue
be
c B
ac
k 
Pa
in
 D
is
ab
ili
ty
 S
ca
le
; R
M
DQ
, R
ol
an
d 
M
or
ris
 D
is
ab
ili
ty
 Q
ue
st
io
nn
ai
re
; S
N
Q,
 S
ta
nd
ar
di
se
d 
N
or
di
c 
Q
ue
st
io
nn
ai
re
 fo
r a
ct
iv
ity
 re
st
ric
tio
ns
; V
AS
, V
is
ua
l A
na
lo
gu
e 
Sc
al
e.
 o
n
 June 10, 2020 at UCSF. Protected by copyright.
http://bjsm.bmj.com/
Br J Sports M
ed: first published as 10.1136/bjsports-2019-101205 on 28 November 2019. Downloaded from 
5Hayden JA, et al. Br J Sports Med 2019;0:1–16. doi:10.1136/bjsports-2019-101205
Review
Table 2 Trial- level and group- level characteristics for 27 IPD included 
studies compared with 29 eligible trials that did not provide data
Trial characteristics
Included IPd trials 
(n=27)
n (%)
not included 
eligible trials 
(n=29)
n (%)
Median number of subjects (IQR) 109 (65–209) 90 (60–132)
Population source
  Healthcare 16 (59) 20 (69)
  Occupational 5 (19) 2 (7)
  General or mixed 6 (22) 7 (24)
Mean age of sample, years (95% CI) 45.7 (45.2 to 46.1) 42.9 (40.1 to 45.6)
Proportion of female sample (95% CI) 55.5 (53.9 to 57.2) 44.3 (36.0 to 52.7)
Mean severity of pain at baseline (95% CI) 53.5 (52.6 to 54.3) 50.9 (44.6 to 57.1)
Number of exercise groups available
  1 exercise group 11 (41) 11 (46)
  2 exercise groups 13 (48) 15 (63)
  3 exercise groups 3 (11) 3 (13)
Number of comparison groups available
  1 comparison group 13 (48) 15 (63)
  2 comparison groups 2 (7) 1 (4)
Exercise group types (46 groups)
  Strengthening 4 (9) 5 (8)
  Stretching 1 (2) 2 (3)
  Core strengthening 10 (22) 10 (15)
  Flexibility/mobilising 1 (2) 0 (0)
  Aerobic 4 (9) 2 (3)
  McKenzie 2 (4) 0 (0)
  Functional restoration 1 (2) 1 (2)
  Yoga 0 (0) 5 (8)
  Other 4 (9) 0 (0)
  Mixed (>2 types) 19 (41) 25 (37)
Design of exercise programme
  Individualised 15 (33) 6 (12)
  Partially individualised 21 (46) 18 (36)
  Standardised 9 (20) 26 (52)
  Not specified 1 (2) 0 (0)
Delivery of exercise programme
  Independent 5 (11) 1 (2)
  Independent with FU 2 (4) 1 (2)
  Group 18 (39) 30 (60)
  One- on- one 17 (37) 16 (32)
  Not specified 4 (9) 2 (4)
Comparison group types (17 groups)
No treatment/usual care comparisons 7 (41) 4 (24)
  No treatment 3 (18) 2 (12)
  Usual care 4 (24) 2 (12)
Other conservative treatment comparisons 10 (59) 13 (77)
  Advice/education 5 (29) 5 (29)
  Back school 1 (6) 0 (0)
  Electrotherapy 0 (0) 4 (24)
  Manual therapy 3 (18) 1 (6)
  NSAIDs/analgesics 0 (0) 1 (6)
  Physiotherapy 0 (0) 1 (6)
  Psychological therapy 1 (6) 0 (0)
  Relaxation 0 (0) 1 (6)
Data presented describe the number and percentage for each characteristic unless otherwise noted.
FU, follow- up; IPD, individual participant data; NSAIDs, non- steroidal anti- inflammatory drugs.
Figure 1 Flow chart of studies and participants included in the 
IPD meta- analysis. IPD, individual participant data; RCT, randomised 
controlled trial.
programme (non- included trials had standardised exercises more 
often) (table 2). Aggregate meta- analysis of published estimates 
comparing treatment effect results from studies included in the 
IPD analysis with those from eligible studies not providing data 
found smaller pain improvement, and similar functional limita-
tion improvement with exercise therapy relative to non- exercise 
comparisons for included studies, compared with eligible studies 
not providing data (pain (0–100 scale) MD (95% CI), included: 
−2.3 (−8.1 to 3.5) vs not included: −10.2 (−16.4 to –4.1) 
(figure 2); functional limitations (0–100 scale) MD (95% CI), 
included: −3.6 (−8.7 to 1.4) vs not included: −2.9 (−6.2 to 
0.3)) (online supplementary appendix 2).
Data from 3514 trial participants were available for our IPD 
meta- analyses (510 participants were excluded from two trials due 
to not having persistent low back pain or having missing data on 
both outcomes): 2568 participants were randomised to receive 
exercise therapy, and 946 participants were randomised to receive 
a non- exercise comparison (142 placebo/no treatment, 125 usual 
care, 679 other conservative treatments, including manual therapy, 
education or psychological therapy; see table 2 for a full list). The 
mean age of participants was 45.7 years (95% CI 45.2 to 46.1) and 
55.5% (1945 of 3504) were female. From trials reporting these 
variables, more than two- thirds of participants reported history of 
low back pain (598 of 877; 68.2%), and 52.4% had been on sick 
leave in the previous 12 months (943 of 1801). At baseline, the 
median low back pain episode duration for participants was 14 
months (IQR=6–48 months; n=1692), with a mean pain intensity 
of 53.5 on a 100- point scale (95% CI 52.6 to 54.3; n=3411); 
63.1% of participants reported leg pain with their low back pain 
(1354 of 2145). Missing data for variables of interest ranged from 
0.2% (sex) to 75% (history of low back pain) (table 3). There was 
heterogeneity in the measurement of potential treatment effect 
modifiers.
IPd integrity
For all included IPD, we were able to replicate aggregate results 
that were reported in each of the associated publications. Of the 27 
IPD data sets that were received, trial information was fully repli-
cated at the data verification stage for 12 data sets. The remaining 
15 trials were partially replicated and required further author 
contact to confirm the data.
Pain and functional limitation outcomes
One- stage random- effects IPD meta- analysis of the included 
trials found that on average exercise therapy was more effective 
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Figure 2 Aggregate meta- analysis results, from published estimates, for studies with IPD available and eligible studies that did not provide data 
for comparison of exercise therapy with any non- exercise comparisons on pain intensity outcome (/100) at the earliest follow- up period. Synthesises 
only trial group data with non- exercise comparison (ie, all other conservative and no treatment/usual care comparisons), similar to primary analysis in 
the related Cochrane review (14 studies/19 groups for IPD and 13 studies/16 groups for IPD eligible, but not available); pain intensity outcome (/100). 
Trials that include only comparisons of different types of exercise are not included. IPD, individual participant data; IV, inverse variance.
than no treatment or usual care on pain outcome (MD (95% CI) 
−10.7 (−14.1 to –7.4); 26 studies, 2466 participants) at short- 
term follow- up, a result most compatible with a clinically 
important 20% smallest worthwhile effect. Other conserva-
tive treatments were found to be more effective than exercise 
therapy, although again not by a clinically important amount 
(MD (95% CI) 3.7 (1.3 to 6.0); 26 studies, 2850 participants).
For functional limitations outcome, exercise therapy was asso-
ciated with a clinically important 23% improvement compared 
with no treatment or usual care (MD (95% CI) −10.2 (−13.1 
to –7.3); 25 studies, 2366 participants) at short- term follow- up. 
Other conservative treatments were found to be more effec-
tive than exercise therapy, although not by clinically important 
amount (MD (95% CI) 1.9 (0.03 to 3.8); 25 studies, 2778 partic-
ipants) at short- term follow- up. We observed similar results 
in meta- analyses of global recovery, where exercise therapy 
was more effective compared with usual care or no treatment 
(OR (95% CI) 3.8 (2.6 to 5.7); 25 studies, 2366 participants) 
and similarly effective as other conservative treatments (OR 
(95% CI) 0.9 (0.7 to 1.1); 25 studies, 2777 participants) at short- 
term follow- up.
exploring individual characteristics that modify exercise 
therapy treatment effect
We identified several variables that may modify the treatment 
effectiveness of exercise therapy relative to non- exercise compar-
ison groups. Observed results were consistent between unad-
justed and adjusted models for each of pain (table 4), functional 
limitations (table 5) and global recovery outcomes (table 6).
For pain outcomes adjusted analyses, figure 3 depicts the MD in 
pain outcomes of exercise compared with non- exercise compari-
sons at short- term follow- up for subgroups of participants based 
on levels of characteristics of potential treatment effect modi-
fiers. We observed clinically important outcome improvement 
with exercise therapy in participants with the following char-
acteristics (exploratory results): normal BMI (compared with 
 o
n
 June 10, 2020 at UCSF. Protected by copyright.
http://bjsm.bmj.com/
Br J Sports M
ed: first published as 10.1136/bjsports-2019-101205 on 28 November 2019. Downloaded from 
7Hayden JA, et al. Br J Sports Med 2019;0:1–16. doi:10.1136/bjsports-2019-101205
Review
Table 3 Characteristics of participants with persistent LBP with 
available follow- up data for IPD analyses (N=3514)
Participant characteristics at baseline Participants, n %
Age (mean, 95% CI) (missing=0.4%) 3499 45.7 (45.2 to 
46.1)
Sex (missing=0.3%)
  Male 1559 44.5
  Female 1945 55.5
High school education (missing=56%)
  High school completed or less 691 45.0
  Beyond high school 843 55.0
Current smoker (missing=57%)
  No 980 65.0
  Yes 527 35.0
Regularly physically active (missing=47%)
  No 916 49.0
  Yes 954 51.0
BMI (mean, 95% CI) (missing=33%) 2352 26.3 (26.1 to 
26.5)
History of LBP (missing=75%)
  No 279 31.8
  Yes 598 68.2
Sick leave (past 12 months) (missing=49%)
  No 858 47.6
  Yes 943 52.4
Work status (missing=22%)
  Unemployed 1076 39.2
  Employed 1669 60.8
Heavy physical demands at work (missing=57%)
  No 976 63.9
  Yes 552 36.1
General health (0–100; mean, 95% CI) 
(missing=56%)
1529 57.3 (56.3 to 
58.2)
Mental health (0–100; mean, 95% CI) 
(missing=71%)
1034 63.4 (62.1 to 
64.7)
Fear avoidance beliefs (0–100; mean; 95% CI) 
(missing=66%)
1182 39.4 (38.1 to 
40.8)
Social support available (missing=56%)
  No 480 30.8
  Yes 1080 69.2
Episode duration (months; median, IQR) 
(missing=52%)
1692 14.0 (6.0 to 48.0)
Pain intensity (0–100; mean, 95% CI) 
(missing=0.3%)
3411 53.5 (52.6 to 
54.3)
Functional limitations (0–100; mean, 95% CI) 
(missing=0.8%)
3247 44.6 (43.8 to 
45.4)
Any leg pain (missing=39%)
  No 791 36.9
  Yes 1354 63.1
Any LBP medication use (missing=44%)
  No 927 47.3
  Yes 1032 52.7
Percentage of missing data for each participant characteristic is noted.
Data presented describe the number and percentage for each characteristic unless 
otherwise noted.
BMI, body mass index; IPD, individual participant data; LBP, low back pain.
underweight and obese), sick leave in the previous 12 months 
and any medication use for low back pain at baseline.
For functional limitation outcomes adjusted analyses, we 
found two variables most compatible with lower (improved) 
functional limitations with receiving exercise treatment relative 
to non- exercise comparisons for treatment–variable interac-
tions: not having heavy physical demands at work (adjusted MD 
(aMD) (95% CI) 6.0 (1.0 to 11.0), p=0.019) and any medica-
tion use for low back pain (aMD (95% CI) −4.8 (−8.7 to –0.9), 
p=0.016). Figure 4 presents the MD in functional limitations 
with exercise therapy compared with other/no treatments for 
subgroups of participants based on potential treatment effect 
modifiers. Participants with the following characteristics had 
better functional limitation outcomes with exercise (exploratory 
results): no heavy physical demands and any medication use for 
low back pain at baseline.
For global recovery outcome with adjusted analyses, any medi-
cation use for low back pain at baseline was most compatible 
with improved outcomes from exercise relative to non- exercise 
comparisons (adjusted OR (95% CI) 1.7 (1.0 to 2.8), p=0.046). 
Figure 5 displays the size of global recovery treatment effects 
for subgroups of participants. Participants with the following 
characteristics reported greater global recovery with exer-
cise compared with other/no treatments (exploratory results): 
normal BMI (compared with underweight and obese), sick leave 
in the previous 12 months, no heavy physical demands, longer 
chronic episode duration of back pain and any medication use 
for low back pain at baseline.
The mean size and direction of the interaction effect for 
potential treatment effect modifiers were consistent across 
moderate- term and long- term follow- up time periods for the 
following characteristics: no physical demands at work and any 
medication use for low back pain. Other potential treatment 
effect modifiers that were important in size and most compatible 
with positive treatment effect modification, at moderate- term 
or long- term follow- up, were the following: for pain outcome, 
beyond high school education, not having a history of low back 
pain, lower fear avoidance beliefs and shorter episode duration; 
for functional limitations outcome, any medication use for low 
back pain; and for global recovery outcome, female sex (online 
supplementary appendices 3–5).
Secondary analyses to explore potential treatment effect modi-
fiers for exercise therapy compared with no treatment/usual care 
comparison groups or with other non- exercise conservative 
comparisons found individuals with lower BMI on average expe-
rienced more improvement on all three outcomes with exercise 
compared with no treatment/usual care comparison groups. 
Individuals with worse baseline function and any medication 
use for low back pain had improved functional limitations with 
exercise compared with either no treatment/usual care compar-
ison groups or other non- exercise conservative comparisons. 
Compared with non- exercise comparisons, individuals with 
the following characteristics had better outcomes with exercise 
treatment: for functional limitation outcome, lower fear avoid-
ance beliefs; and for global recovery outcome, any medication 
use for low back pain (online supplementary appendices 6–8).
dISCuSSIon
In this study, we used original data from 27 randomised 
controlled trials of exercise therapy to explore individual char-
acteristics and identify subgroups based on participants’ likely 
response to exercise treatment. One- stage random- effects meta- 
analysis of data from included trials found exercise therapy to 
be more effective than no treatment or usual care on pain, func-
tional limitations and global recovery outcomes at short- term 
follow- up, most compatible with a clinically important improve-
ment. Exercise therapy was observed to be similarly effective to 
 o
n
 June 10, 2020 at UCSF. Protected by copyright.
http://bjsm.bmj.com/
Br J Sports M
ed: first published as 10.1136/bjsports-2019-101205 on 28 November 2019. Downloaded from 
8 Hayden JA, et al. Br J Sports Med 2019;0:1–16. doi:10.1136/bjsports-2019-101205
Review
Table 4 Size and statistical significance of treatment–variable interactions (unadjusted and adjusted results) on continuous pain outcome (0–100) 
at follow- up closest to 3 months*
Variable
unadjusted Adjusted
Studies Participants
Interaction
Md (95% CI) P value Studies Participants
Interaction
Md (95% CI) P value
Age (years) 26 3091 0.09 (−0.05 to 0.23) 0.22 26 3091 0.09 (−0.05 to 0.23) 0.22
Sex 26 3095     26 3091     
  Male − − − −
  Female −0.98 (−4.49 to 2.53) 0.59 −0.96 (−4.39 to 2.46) 0.58
High school education 12 1401     12 1399     
  High school or less − − − −
  Beyond high school −3.94 (−8.90 to 1.02) 0.12 −3.69 (−8.65 to 1.27) 0.15
Current smoker 9 1411     9 1407     
  No − − − −
  Yes 2.07 (−3.15 to 7.29) 0.44 1.38 (−3.86 to 6.63) 0.61
Regular physical activity 11 1695     11 1693     
  No − − − −
  Yes −1.05 (−5.79 to 3.68) 0.66 −0.67 (−5.4 to 4.06) 0.78
BMI 17 2173 0.23 (−0.27 to 0.74) 0.37 17 2170 0.22 (−0.27 to 0.71) 0.38
History of LBP 8 827     8 827     
  No − − − −
  Yes −4.03 (−13.88 to 5.82) 0.42 −3.92 (−13.76 to 5.92) 0.44
Sick leave (past 12 months) 14 1578     14 1575     
  No − − − −
  Yes −2.27 (−9.15 to 4.61) 0.52 −2.15 (−8.92 to 4.62) 0.53
Work status 18 2446     18 2444     
  Unemployed − − − −
  Employed −3.81 (−9.07 to 1.45) 0.16 −4.22 (−9.26 to 0.82) 0.10
Heavy physical demands 8 1388     8 1386     
  No − − − −
  Yes 4.45 (−1.84 to 10.74) 0.17 4.92 (−1.35 to 11.19) 0.12
General health (0–100) 10 1319 0.05 (−0.11 to 0.20) 0.54 10 1316 0.05 (−0.11 to 0.21) 0.55
Mental health (0–100) 6 877 −0.05 (−0.19 to 0.10) 0.54 6 874 −0.04 (−0.18 to 0.11) 0.61
Fear avoidance beliefs (0–100) 8 1012 0.08 (−0.03 to 0.20) 0.16 8 1011 0.09 (−0.03 to 0.20) 0.15
Social support 10 1451     10 1450     
  No − − − −
  Yes −1.05 (−5.65 to 3.55) 0.66 −1.38 (−5.97 to 3.20) 0.55
Episode duration (months) 13 1572 0.02 (−0.03 to 0.07) 0.37 13 1569 0.02 (−0.04 to 0.08) 0.58
Functional limitations (0–100) 24 2880 0.01 (−0.08 to 0.11) 0.81 24 2876 0.02 (−0.07 to 0.12) 0.66
Pain intensity (0–100) 26 3095 −0.06 (−0.15 to 0.03) 0.23 26 3091 −0.05 (−0.14 to 0.04) 0.26
Any leg pain 14 1837     14 1833     
  No − − − −
  Yes 1.60 (−3.57 to 6.77) 0.54 1.46 (−3.73 to 6.64) 0.58
Any LBP medication use 13 1776     13 1774     
  No − − − −
  Yes −4.04 (−9.66 to 1.58) 0.16 −3.90 (−9.40 to 1.60) 0.16
A negative interaction coefficient indicates decreased pain for the variable level (eg, female) with exercise vs any non- exercise comparison (ie, all other conservative and no 
treatment/usual care comparisons.
*Unadjusted models include baseline pain, potential treatment effect- modifying variable, treatment group (exercise or comparison treatment), and trial at the random- effects 
level and the variable–treatment group interaction at the fixed- effects level. Adjusted models add age and sex (at the random- effects level). All participant- level covariates are 
centred around their trial- specific means.
BMI, body mass index; LBP, low back pain; MD, mean difference.
other included comparison treatments (here including manual 
therapy, education or psychological therapy) for all outcomes. 
However, these results should be interpreted cautiously as the 
trials included in this study may underestimate exercise treat-
ment effect and represent fewer than 10% of the randomised 
controlled trials now available.
Comparisons of trial characteristics were not noticeably 
different from eligible trials not providing data. However, 
analysis limited to other treatment group comparisons suggested 
that the average treatment effect for exercise therapy was smaller 
and not clinically important for studies providing IPD (MD = 
-2.3 for pain outcome) compared to the effect of treatment in 
eligible trials not providing IPD (MD = -10.2 for pain outcome).
Our study has provided exploratory evidence that not having 
heavy physical demands at work and using pain medication 
are potential treatment effect modifiers for exercise therapy 
 o
n
 June 10, 2020 at UCSF. Protected by copyright.
http://bjsm.bmj.com/
Br J Sports M
ed: first published as 10.1136/bjsports-2019-101205 on 28 November 2019. Downloaded from 
9Hayden JA, et al. Br J Sports Med 2019;0:1–16. doi:10.1136/bjsports-2019-101205
Review
Table 5 Size and statistical significance of treatment–variable interactions (unadjusted and adjusted results) on continuous functional outcome 
(0–100) at follow- up closest to 3 months*
Variable
unadjusted Adjusted
Studies Participants
Interaction
Md (95% CI) P value Studies Participants
Interaction
Md (95% CI) P value
Age (years) 25 2996 0.07 (−0.04 to 0.19) 0.21 25 2996 0.07 (−0.04 to 0.19) 0.21
Sex 25 3000     25 2996     
  Male − − − −
  Female −1.62 (−4.38 to 1.15) 0.25 −1.71 (−4.44 to 1.02) 0.22
High school education 10 1204     10 1202     
  High school or less − − − −
  Beyond high school −0.53 (−4.83 to 3.77) 0.81 −0.24 (−4.54 to 4.05) 0.91
Current smoker 9 1420     9 1416     
  No − − − −
  Yes 0.16 (−3.99 to 4.30) 0.94 −0.36 (−4.52 to 3.80) 0.87
Regular physical activity 12 1758     12 1756     
  No − − − −
  Yes −0.96 (−4.59 to 2.67) 0.60 −0.75 (−4.38 to 2.89) 0.69
BMI 15 1984 0.11 (−0.31 to 0.52) 0.61 15 1981 0.11 (−0.30 to 0.52) 0.60
History of LBP 8 830     8 830     
  No − − − −
  Yes 0.16 (−8.23 to 8.56) 0.97 0.39 (−7.99 to 8.76) 0.93
Sick leave (past 12 months) 13 1451     13 1448     
  No − − − −
  Yes −0.35 (−6.65 to 5.94) 0.91 −0.03 (−6.24 to 6.17) 0.99
Work status 17 2321     17 2319     
  Unemployed − − − −
  Employed 0.96 (−2.93 to 4.85) 0.63 0.58 (−3.24 to 4.40) 0.76
Heavy physical demands 8 1391     8 1389     
  No − − − −
  Yes 5.81 (0.73 to 10.88) 0.025 6.02 (1.00 to 11.04) 0.019
General health (0–100) 10 1337 −0.06 (−0.25 to 0.14) 0.56 10 1334 −0.06 (−0.25 to 0.14) 0.56
Mental health (0–100) 7 956 −0.03 (−0.20 to 0.15) 0.75 7 953 −0.02 (−0.19 to 0.15) 0.82
Fear avoidance beliefs (0–100) 9 1110 0.09 (−0.003 to 0.18) 0.059 9 1109 0.09 (−0.002 to 0.18) 0.054
Social support 9 1381     9 1380     
  No − − − −
  Yes 2.2 (−2.08 to 6.48) 0.31 1.94 (−2.40 to 6.29) 0.38
Episode duration (months) 13 1573 0.01 (−0.01 to 0.04) 0.29 13 1570 0.02 (−0.01 to 0.04) 0.25
Functional limitations (0–100) 25 3000 −0.08 (−0.18 to 0.02) 0.14 25 2996 −0.06 (−0.16 to 0.03) 0.21
Pain intensity (0–100) 24 2923 0.03 (−0.04 to 0.10) 0.38 24 2919 0.03 (−0.04 to 0.10) 0.36
Any leg pain 15 1950     15 1946     
  No − − − −
  Yes 0.86 (−3.21 to 4.94) 0.68 0.54 (−3.53 to 4.61) 0.80
Any LBP medication use 13 1795     13 1793     
  No − − − −
  Yes −5.11 (−9.03 to 1.19) 0.011 −4.81 (−8.72 to 0.90) 0.016
A negative interaction coefficient indicates decreased function for the variable level (eg, female) with exercise vs any non- exercise comparison (ie, all other conservative and no 
treatment/usual care comparisons.
*Unadjusted models include baseline functional limitations, potential treatment effect- modifying variable, treatment group (exercise or comparison treatment), and trial at the 
random- effects level and the variable–treatment group interaction at the fixed- effects level. Adjusted models add age and sex (at the random- effects level). All participant- level 
covariates are centred around their trial- specific means.
BMI, body mass index; LBP, low back pain; MD, mean difference.
outcomes compared with other treatments at short- term 
follow- up. This indicates that individuals with these characteris-
tics may benefit more from exercise therapy. One could hypoth-
esise that characteristics that may facilitate compliance with an 
active treatment programme (eg, using medication to alleviate 
low back pain symptoms, and not having physical demands 
at work which could lead to strain and/or a flare up of symp-
toms) may be associated with improved outcomes with exercise 
compared with other treatments. Lower BMI was consistently 
associated with improved outcomes from exercise interventions 
compared with usual care or no treatment at the follow- up 
period closest to 3 months.
These results suggest two directions for future research to 
advance management of persistent low back pain. First, further 
research is needed to validate and extend our findings. We 
tested many potential effect modifiers, so our findings may be 
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Table 6 Size and statistical significance of treatment–variable interactions (unadjusted and adjusted results) on important global recovery in pain 
or functional outcome (dichotomous) at follow- up closest to 3 months*
Variable
unadjusted Adjusted
Studies (n) Participants (n)
Interaction
oR (95% CI) P value Studies (n) Participants (n)
Interaction
oR (95% CI) P value
Age (years) 25 2995 1.01 (0.99 to 1.02) 0.43 25 2995 1.01 (0.99 to 1.02) 0.43
Sex 25 2995     25 2995     
  Male − − − −
  Female 1.33 (0.91 to 1.94) 0.15 1.32 (0.90 to 1.93) 0.16
High school education 10 1204     10 1202     
  High school or less − − − −
  Beyond high school 1.32 (0.73 to 2.40) 0.36 1.32 (0.72 to 2.40) 0.37
Current smoker 9 1421     9 1417     
  No − − − −
  Yes 0.98 (0.54 to 1.80) 0.96 1.04 (0.56 to 1.93) 0.90
Regular physical activity 12 1758     12 1756     
  No − − − −
  Yes 0.94 (0.56 to 1.57) 0.80 0.90 (0.54 to 1.52) 0.70
BMI 15 1986 0.95 (0.89 to 1.00) 0.067 15 1983 0.95 (0.89 to 1.00) 0.054
History of LBP 8 830     8 830     
  No − − − −
  Yes 1.05 (0.40 to 2.79) 0.92 1.05 (0.39 to 2.78) 0.93
Sick leave (past 12 months) 13 1450     13 1447     
  No − − − −
  Yes 1.33 (0.61 to 2.92) 0.48 1.26 (0.57 to 2.80) 0.56
Work status 17 2319     17 2317     
  Unemployed − − − −
  Employed 0.93 (0.56 to 1.55) 0.78 0.94 (0.56 to 1.58) 0.82
Heavy physical demands 8 1393     8 1391     
  No − − − −
  Yes 0.56 (0.26 to 1.21) 0.14 0.55 (0.26 to 1.19) 0.13
General health (0–100) 10 1335 1.00 (0.98 to 1.03) 0.88 10 1332 1.00 (0.98 to 1.03) 0.92
Mental health (0–100) 7 954 0.99 (0.97 to 1.02) 0.55 7 951 0.99 (0.97 to 1.01) 0.46
Fear avoidance beliefs (0–100) 9 1106 1.00 (0.98 to 1.01) 0.69 9 1105 1.00 (0.98 to 1.01) 0.71
Social support 9 1380     9 1379     
  No − − − −
  Yes 1.14 (0.66 to 1.97) 0.64 1.17 (0.67 to 2.02) 0.58
Episode duration (months) 13 1575 1.00 (1.00 to 1.01) 0.41 13 1572 1.00 (1.00 to 1.01) 0.43
Functional limitations (0–100) 25 2999 1.01 (1.00 to 1.02) 0.28 25 2995 1.01 (0.99 to 1.02) 0.32
Pain intensity (0–100) 24 2925 1.00 (0.99 to 1.01) 0.79 24 2921 1.00 (0.99 to 1.01) 0.81
Any leg pain 15 1950     15 1946     
  No − − − −
  Yes 0.98 (0.54 to 1.78) 0.95 1.01 (0.55 to 1.86) 0.97
Any LBP medication use 13 1795     13 1793     
  No − − − −
  Yes 1.72 (1.03 to 2.85) 0.037 1.68 (1.01 to 2.81) 0.046
An interaction coefficient above 1 indicates increased likelihood of recovery for the variable level (eg, female) with exercise vs any non- exercise comparison (ie, all other 
conservative and no treatment/usual care comparisons).
*Unadjusted models include baseline functional limitations, potential treatment effect- modifying variable, treatment group (exercise or comparison treatment), and trial at the 
random- effects level and the variable–treatment group interaction at the fixed- effects level. Adjusted models add age and sex (at the random- effects level). All participant- level 
covariates are centred around their trial- specific means.
BMI, body mass index; LBP, low back pain.
coincidental. Future trials of exercise therapy, including prospec-
tively planned multicentre trials, should consistently measure 
and test these and other theoretically driven potential treatment 
effect modifiers. Second, future studies may test incorporation 
of these characteristics into prediction models to select individ-
uals for exercise treatment. If prediction models are confirmed 
accurate in future studies, and with alternate strategies for 
subgroups who do poorly with exercise, then persistent low back 
pain outcomes could be improved with more tailoring of treat-
ments received.
IPD meta- analysis is the gold standard for systematic review,24 
and we followed current recommendations for robust analyses. 
IPD meta- analysis has three key advantages which have bene-
fited this study. First, the availability of data from 27 trials 
identified through a systematic review and rated as moderate 
to low risk of bias resulted in a large sample size available to 
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Figure 3 Treatment effect mean differences in pain outcome at follow- up closest to 3 months for subgroups of potential treatment effect modifiers; 
for presentation reasons, continuous variables were categorised at clinically relevant cut- points when possible or based on the observed median. We 
used uncentred values of the potential treatment effect modifier to calculate the mean treatment effect across categories, appropriately adjusted for 
covariates centred around their trial- specific means. BMI, body mass index; LBP, low back pain.
investigate subgroup effects. Second, we were able to attain 
consistent presentation of data; direct derivation of informa-
tion independent of reporting and standardisation of analyses 
across studies allowed more usable data for meta- analyses. 
Third, we were able to conduct additional analyses to explore 
heterogeneity (more extensive use of available data to explore 
trial- level and participant- level factors in meta- analyses, and 
assessment of the variation in summary effects within partici-
pant subgroups to allow better understanding of the effects of 
exercise treatment).
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Figure 4 Treatment effect mean difference in functional outcome at follow- up closest to 3 months for subgroups of potential treatment effect 
modifiers; for presentation reasons, continuous variables were categorised at clinically relevant cut- points when possible or based on the observed 
median. We used uncentred values of the potential treatment effect modifier to calculate the mean treatment effect across categories, appropriately 
adjusted for covariates centred around their trial- specific means. BMI, body mass index; LBP, low back pain.
A limitation of our IPD study is the small sample size of 
included trials. Small trials, common with low back pain treat-
ment studies, are not individually powered to detect a mean-
ingful treatment or moderating effect, may be of lower quality, 
or reflect publication bias. A benefit of meta- analysis is providing 
sufficient power through synthesis. However, inclusion of invalid 
trials in our study may have led to misleading results, partic-
ularly related to overall treatment effect. We addressed study 
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Figure 5 Treatment effect global recovery outcome at follow- up closest to 3 months for subgroups of potential treatment effect modifiers; for 
presentation reasons, continuous variables were categorised at clinically relevant cut- points when possible or based on the observed median. We 
used uncentred values of the potential treatment effect modifier to calculate the mean treatment effect across categories, appropriately adjusted for 
covariates centred around their trial- specific means. BMI, body mass index; LBP, low back pain.
internal validity by selecting trials judged to not be at high risk 
of bias using the Cochrane Back and Neck group recommended 
criteria, but may have missed other sources of bias. We do not 
think that systematic bias related to our primary treatment effect 
modification results is likely; however, our results should still be 
interpreted cautiously. A challenge of smaller studies that should 
be considered by future researchers undertaking IPD meta- 
analyses relates to feasibility. Small studies add little information 
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relative to the time required to test, map and include their data. 
However, this should be balanced against enhanced generalis-
ability of results with trials representing real heterogeneity in 
populations and exercise interventions.
A second limitation of this study was the inconsistent avail-
ability and measurement of some individual characteristics, 
limiting the ability to assess all potential treatment effect modi-
fiers with the most valid, reliable continuous measures. Although 
the overall sample size was large, some potential treatment effect 
modifiers were available and measured consistently in only a 
small subset of studies. For example, 8 trials with 1386 partici-
pants provided usable data on heavy physical demands at work, 
and 13 trials with 1774 participants provided usable data on 
use of pain medication at baseline, analysed as a dichotomous 
measure, including analgesic, anti- inflammatory or opioids. 
Almost 40% of trials compared different exercise types, with no 
non- exercise comparison available.
We were unable to explore treatment effect modifiers for 
specific exercise therapies, non- exercise comparisons, or for no 
treatment separate from placebo or usual care comparisons due 
to insufficient homogeneous types across included trials. Further-
more, we were unable to investigate some potential treatment 
effect modifiers we had originally planned due to low availability 
across studies, including presence and number of comorbidities, 
alcohol use and socioeconomic status. While we only received 
data from approximately half of requested trials and the 
observed effect of exercise versus other comparisons was smaller 
for pain outcomes, trial- level characteristics did not significantly 
differ between those received and requested. A commonly stated 
benefit of IPD meta- analysis is a more consistent presentation 
of data and approach to analysis across included trials, allowing 
for more homogeneity. However, this is achievable only if the 
necessary participant characteristics and outcome variables are 
reported; in our study we did not find our IPD meta- analysis to 
have lower heterogeneity than previous aggregate meta- analyses. 
A limitation of our IPD analysis includes our assumption of 
linear interactions for continuous variables, which may have 
missed non- linear relationships. Finally, a challenge of the IPD 
approach was the considerable amount of time and effort that 
was involved in gathering, testing and compiling data from indi-
vidual studies, which were published before 2013. However, we 
think that it is unlikely that newer trial data would be different 
in treatment effect modification results, which is the focus of 
this project.
Patients with low back pain are heterogeneous and the treat-
ment is complex. We will need large data sets of reliably and 
consistently measured variables to better understand treatment 
effect modifiers and identify relevant treatment subgroups for 
exercise overall and for specific types of exercise (ie, yoga, 
aerobic exercise and so on). Specifically, the factors that we 
identified in our study to be potential treatment effect modi-
fiers should be further investigated. Future trials should 
measure a comprehensive set of variables to define potential 
subgroups, evaluate treatment effect modification and include 
non- exercise comparisons. This is unlikely to be feasible with 
small individual studies, so it will need to be facilitated by 
increased international collaboration, prospective planning 
of multisite and multicountry trials, standardising measure-
ment of prognostic factors, and potentially by sharing of data 
through accessible repositories. Future prospective coordi-
nation and collaboration for more consistent data collection 
will help researchers identify treatment effect modifiers. This 
will further advance a personalised management approach for 
persistent low back pain.
ConCluSIonS
Our IPD meta- analysis combined data from 27 randomised 
trials, which allowed us to examine a large sample with consis-
tent data. We assessed the effectiveness of exercise therapy to 
provide context to our study and explored the impact of poten-
tial treatment effect modifiers. In our sample, exercise therapy 
was minimally effective for persistent non- specific low back pain 
outcomes, and it appears that for individuals using medication 
for low back pain, and possibly for those with no heavy phys-
ical demands at work, they may benefit more from exercise than 
other treatments. This study provides potentially useful informa-
tion to help design future studies of exercise interventions that 
are better matched to specific subgroups.
What is already known
 ► While there is no consensus on the best course of treatment, 
exercise therapy is on average moderately effective for 
persistent low back pain and is recommended by clinical 
guidelines.
 ► To choose the most appropriate care for patients, it is 
important to understand which individual characteristics (eg, 
work status, pain medication use) are associated with better 
or worse treatment outcomes.
What are the new findings
 ► The research team obtained data sets for 27 randomised 
controlled trials, each of which examined the impact of 
various forms of exercise on pain or function for people with 
persistent low back pain; trial data were merged into a large 
data set of 3514 individuals and were analysed.
 ► Exercise therapy was more effective than other treatments 
for people who did not have heavy physical demands at work 
and who used medication to treat low back pain.
 ► Future studies of exercise therapy should prospectively test 
the modifying effect of factors identified in this study, and 
other untested factors, alone and in combination.
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